

MarÃ-a L GarcÃ-a

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4562551/publications.pdf>

Version: 2024-02-01

95
papers

5,985
citations

61984

43
h-index

74163

75
g-index

95
all docs

95
docs citations

95
times ranked

6857
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment. <i>International Journal of Pharmaceutics</i> , 2022, 612, 121379.	5.2	15
2	Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation. <i>Pharmaceutics</i> , 2022, 14, 285.	4.5	15
3	Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. <i>Heliyon</i> , 2022, 8, e08938.	3.2	48
4	Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges. <i>Epilepsia Open</i> , 2022, 7, .	2.4	14
5	Exudative versus Nonexudative Age-Related Macular Degeneration: Physiopathology and Treatment Options. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2592.	4.1	27
6	Permeability, anti-inflammatory and anti-VEGF profiles of steroidal-loaded cationic nanoemulsions in retinal pigment epithelial cells under oxidative stress. <i>International Journal of Pharmaceutics</i> , 2022, 617, 121615.	5.2	7
7	Lipid Nanoparticles for the Posterior Eye Segment. <i>Pharmaceutics</i> , 2022, 14, 90.	4.5	28
8	Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. <i>Nanomedicine</i> , 2021, 16, 19-35.	3.3	18
9	Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders. <i>Nanomedicine</i> , 2021, 16, 401-414.	3.3	6
10	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. <i>Journal of Nanobiotechnology</i> , 2021, 19, 122.	9.1	60
11	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4305.	2.5	26
12	Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4983.	4.1	40
13	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. <i>Toxics</i> , 2021, 9, 195.	3.7	11
14	Calcium hydroxide-loaded PLGA biodegradable nanoparticles as an intracanal medicament. <i>International Endodontic Journal</i> , 2021, 54, 2086-2098.	5.0	20
15	Surface-Modified Multifunctional Thymol-Loaded Biodegradable Nanoparticles for Topical Acne Treatment. <i>Pharmaceutics</i> , 2021, 13, 1501.	4.5	15
16	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 812-839.	6.4	45
17	Mono- and Dicationic DABCO/Quinuclidine Composed Nanomaterials for the Loading of Steroidal Drug: 32 Factorial Design and Physicochemical Characterization. <i>Nanomaterials</i> , 2021, 11, 2758.	4.1	9
18	Stabilization by Nano Spray Dryer of Pioglitazone Polymeric Nanosystems: Development, In Vivo, Ex Vivo and Synchrotron Analysis. <i>Pharmaceutics</i> , 2021, 13, 1751.	4.5	3

#	ARTICLE	IF	CITATIONS
19	Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation. <i>Pharmaceutics</i> , 2021, 13, 1698.	4.5	28
20	DABCO-Customized Nanoemulsions: Characterization, Cell Viability and Genotoxicity in Retinal Pigmented Epithelium and Microglia Cells. <i>Pharmaceutics</i> , 2021, 13, 1652.	4.5	11
21	Development of topical eye-drops of lactoferrin-loaded biodegradable nanoparticles for the treatment of anterior segment inflammatory processes. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121188.	5.2	20
22	Thymol-loaded PLGA nanoparticles: an efficient approach for acne treatment. <i>Journal of Nanobiotechnology</i> , 2021, 19, 359.	9.1	31
23	Development and Characterization of Nanoemulsions for Ophthalmic Applications: Role of Cationic Surfactants. <i>Materials</i> , 2021, 14, 7541.	2.9	20
24	State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. <i>Journal of Nanobiotechnology</i> , 2020, 18, 156.	9.1	38
25	Nanostructured lipid carriers loaded with Halobetasol propionate for topical treatment of inflammation: Development, characterization, biopharmaceutical behavior and therapeutic efficacy of gel dosage forms. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119480.	5.2	13
26	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. <i>Nanomedicine</i> , 2020, 15, 1239-1261.	3.3	68
27	Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs). <i>Nanomaterials</i> , 2020, 10, 560.	4.1	83
28	Retinal Drug Delivery: Rethinking Outcomes for the Efficient Replication of Retinal Behavior. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 4258.	2.5	4
29	Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. <i>Nanomaterials</i> , 2020, 10, 292.	4.1	769
30	Diabetic Retinopathy and Ocular Melanoma: How Far We Are?. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2777.	2.5	1
31	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. <i>Nanomaterials</i> , 2020, 10, 720.	4.1	44
32	Recent Advances on Antitumor Agents-loaded Polymeric and Lipid-based Nanocarriers for the Treatment of Brain Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 1316-1330.	1.9	17
33	In Vitro Cytotoxicity of Oleanolic/Ursolic Acids-Loaded in PLGA Nanoparticles in Different Cell Lines. <i>Pharmaceutics</i> , 2019, 11, 362.	4.5	52
34	Development of Chitosan/Silver Sulfadiazine/Zeolite Composite Films for Wound Dressing. <i>Pharmaceutics</i> , 2019, 11, 535.	4.5	47
35	Sirtuins and SIRT6 in Carcinogenesis and in Diet. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4945.	4.1	19
36	Trends in Atopic Dermatitisâ€”From Standard Pharmacotherapy to Novel Drug Delivery Systems. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5659.	4.1	43

#	ARTICLE	IF	CITATIONS
37	Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome”Review of Classical and New Compounds: Part-I. <i>Pharmaceutics</i> , 2019, 12, 152.	3.8	95
38	Therapeutic Interventions for Countering Leishmaniasis and Chagas”s Disease: From Traditional Sources to Nanotechnological Systems. <i>Pathogens</i> , 2019, 8, 119.	2.8	21
39	Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome”Strategies for In Vivo Administration: Part-II. <i>Journal of Clinical Medicine</i> , 2019, 8, 1332.	2.4	43
40	Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. <i>Pharmaceutics</i> , 2019, 11, 460.	4.5	115
41	Development of Halobetasol-loaded nanostructured lipid carrier for dermal administration: Optimization, physicochemical and biopharmaceutical behavior, and therapeutic efficacy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 20, 102026.	3.3	25
42	Current Applications of Nanoemulsions in Cancer Therapeutics. <i>Nanomaterials</i> , 2019, 9, 821.	4.1	147
43	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model. <i>Journal of Controlled Release</i> , 2019, 301, 62-75.	9.9	207
44	Ocular penetration of fluorometholone-loaded PEG-PLGA nanoparticles functionalized with cell-penetrating peptides. <i>Nanomedicine</i> , 2019, 14, 3089-3104.	3.3	41
45	Optimization of nimesulide-loaded solid lipid nanoparticles (SLN) by factorial design, release profile and cytotoxicity in human Colon adenocarcinoma cell line. <i>Pharmaceutical Development and Technology</i> , 2019, 24, 616-622.	2.4	22
46	Comparison of migration disturbance potency of epigallocatechin gallate (EGCG) synthetic analogs and EGCG PEGylated PLGA nanoparticles in rat neurospheres. <i>Food and Chemical Toxicology</i> , 2019, 123, 195-204.	3.6	10
47	Thiazolidinedione as an alternative to facilitate oral administration in geriatric patients with Alzheimer's disease. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 129, 173-180.	4.0	10
48	In-situ forming gels containing fluorometholone-loaded polymeric nanoparticles for ocular inflammatory conditions. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 175, 365-374.	5.0	49
49	Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1073-1085.	3.3	60
50	Optimization, Biopharmaceutical Profile and Therapeutic Efficacy of Pioglitazone-loaded PLGA-PEG Nanospheres as a Novel Strategy for Ocular Inflammatory Disorders. <i>Pharmaceutical Research</i> , 2018, 35, 11.	3.5	27
51	Memantine loaded PLGA PEGylated nanoparticles for Alzheimer”s disease: in vitro and in vivo characterization. <i>Journal of Nanobiotechnology</i> , 2018, 16, 32.	9.1	163
52	Memantine”Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. <i>Small</i> , 2018, 14, 1701808.	10.0	77
53	Development of Pranoprofen Loaded Nanostructured Lipid Carriers to Improve Its Release and Therapeutic Efficacy in Skin Inflammatory Disorders. <i>Nanomaterials</i> , 2018, 8, 1022.	4.1	10
54	Skin-controlled release lipid nanosystems of pranoprofen for the treatment of local inflammation and pain. <i>Nanomedicine</i> , 2018, 13, 2397-2413.	3.3	12

#	ARTICLE	IF	CITATIONS
55	Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide. <i>Molecular Pharmaceutics</i> , 2018, 15, 5005-5018.	4.6	14
56	PPAR γ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 5577-5590.	6.7	52
57	Development of fluorometholone-loaded PLGA nanoparticles for treatment of inflammatory disorders of anterior and posterior segments of the eye. <i>International Journal of Pharmaceutics</i> , 2018, 547, 338-346.	5.2	50
58	Development of a Nasal Donepezil-loaded Microemulsion for the Treatment of Alzheimer's Disease: in vitro and ex vivo Characterization. <i>CNS and Neurological Disorders - Drug Targets</i> , 2018, 17, 43-53.	1.4	40
59	Comparative Study of Ex Vivo Transmucosal Permeation of Pioglitazone Nanoparticles for the Treatment of Alzheimer's Disease. <i>Polymers</i> , 2018, 10, 316.	4.5	36
60	New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APP ^{swE} /PS1 ^{dE9} . <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1171-1182.	3.3	64
61	Penetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2017, 120, 98-106.	4.3	27
62	Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2475.	4.1	12
63	Human Skin Permeation Studies with PPAR β Agonist to Improve Its Permeability and Efficacy in Inflammatory Processes. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2548.	4.1	20
64	Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. <i>Neural Plasticity</i> , 2016, 2016, 1-15.	2.2	200
65	Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo , in vitro and ex vivo studies. <i>International Journal of Pharmaceutics</i> , 2016, 502, 161-169.	5.2	101
66	In vitro , ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration. <i>International Journal of Pharmaceutics</i> , 2016, 511, 719-727.	5.2	60
67	Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 108, 235-252.	4.3	203
68	Ex vivo permeation of carprofen from nanoparticles: A comprehensive study through human, porcine and bovine skin as anti-inflammatory agent. <i>International Journal of Pharmaceutics</i> , 2016, 501, 10-17.	5.2	31
69	Biopharmaceutical profile of hydrogels containing pranoprofen-loaded PLGA nanoparticles for skin administration: In vitro , ex vivo and in vivo characterization. <i>International Journal of Pharmaceutics</i> , 2016, 501, 350-361.	5.2	35
70	Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery. <i>International Journal of Nanomedicine</i> , 2015, 10, 609.	6.7	67
71	Design and optimization of oleanolic/ursolic acid-loaded nanoplatfoms for ocular anti-inflammatory applications. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 521-530.	3.3	60
72	Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 95, 261-270.	4.3	91

#	ARTICLE	IF	CITATIONS
73	Development and validation of a high-performance liquid chromatography method for the quantification of ursolic/oleanic acids mixture isolated from <i>Plumeria obtusa</i> . <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 983-984, 111-116.	2.3	20
74	Effect of cryoprotectants on the reconstitution of silica nanoparticles produced by sol-gel technology. <i>Journal of Thermal Analysis and Calorimetry</i> , 2015, 120, 1001-1007.	3.6	15
75	Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 93, 118-126.	4.3	85
76	Design and elaboration of freeze-dried PLGA nanoparticles for the transcorneal permeation of carprofen: Ocular anti-inflammatory applications. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 136, 935-943.	5.0	38
77	Current nanotechnology approaches for the treatment and management of diabetic retinopathy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 95, 307-322.	4.3	72
78	Design of Nanosuspensions and Freeze-Dried PLGA Nanoparticles as a Novel Approach for Ophthalmic Delivery of Pranoprofen. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 3153-3164.	3.3	51
79	Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 123, 452-460.	5.0	85
80	Surface engineering of silica nanoparticles for oral insulin delivery: Characterization and cell toxicity studies. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 123, 916-923.	5.0	93
81	Design of cationic lipid nanoparticles for ocular delivery: Development, characterization and cytotoxicity. <i>International Journal of Pharmaceutics</i> , 2014, 461, 64-73.	5.2	118
82	Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery. <i>International Journal of Pharmaceutics</i> , 2014, 473, 627-635.	5.2	91
83	Validation of a high performance liquid chromatography method for the stabilization of epigallocatechin gallate. <i>International Journal of Pharmaceutics</i> , 2014, 475, 181-190.	5.2	39
84	Flurbiprofen PLGA-PEG nanospheres: Role of hydroxy- β -cyclodextrin on ex vivo human skin permeation and in vivo topical anti-inflammatory efficacy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2013, 110, 339-346.	5.0	49
85	Experimental factorial design applied to mucoadhesive lipid nanoparticles via multiple emulsion process. <i>Colloids and Surfaces B: Biointerfaces</i> , 2012, 100, 84-89.	5.0	56
86	Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 1034-1041.	3.3	80
87	Skin Permeation of Cacalol, Cacalone and 6-epi-Cacalone Sesquiterpenes from a Nanoemulsion. <i>Natural Product Communications</i> , 2012, 7, 1934578X1200700.	0.5	3
88	Role of hydroxypropyl- β -cyclodextrin on freeze-dried and gamma-irradiated PLGA and PLGA-PEG diblock copolymer nanospheres for ophthalmic flurbiprofen delivery. <i>International Journal of Nanomedicine</i> , 2012, 7, 1357.	6.7	80
89	Improved and Safe Transcorneal Delivery of Flurbiprofen by NLC and NLC-Based Hydrogels. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 707-725.	3.3	63
90	Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. <i>Colloids and Surfaces B: Biointerfaces</i> , 2011, 86, 158-165.	5.0	222

#	ARTICLE	IF	CITATIONS
91	Feasibility of Lipid Nanoparticles for Ocular Delivery of Anti-Inflammatory Drugs. <i>Current Eye Research</i> , 2010, 35, 537-552.	1.5	117
92	Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). <i>Colloids and Surfaces B: Biointerfaces</i> , 2010, 75, 538-542.	5.0	118
93	Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. <i>Colloids and Surfaces B: Biointerfaces</i> , 2010, 81, 412-421.	5.0	156
94	Nanomedicines for ocular NSAIDs: safety on drug delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2009, 5, 394-401.	3.3	196
95	PLGA nanospheres for the ocular delivery of flurbiprofen: Drug release and interactions. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 5306-5317.	3.3	126